DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel, Globally-Recognized Law Firm about Leading AbbVie Inc. Class Action Lawsuit Pharmaceutical Investing
ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - ABBV Pharmaceutical Investing
U.S. Food and Drug Administration Approves Two Opdivo® -Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Pharmaceutical Investing
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, MYPS and ARQQ Pharmaceutical Investing
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib in Ulcerative Colitis Pharmaceutical Investing
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab in Crohn's Disease Pharmaceutical Investing
Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy Pharmaceutical Investing
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV Pharmaceutical Investing
Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101 Pharmaceutical Investing
Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference Pharmaceutical Investing
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis Life Science Investing
LAWSUITS FILED AGAINST ABBV, AXSM and OKTA - Jakubowitz Law Pursues Shareholders Claims Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
